EUVIMEDEUVIMED entdecken
Leserbrief

Feasibility of Sildenafil for the Prevention of Right Heart Failure After Continuous-Flow Left Ventricular Assist Device Implantation: The REVAD Trial

Nowell M Fine, Owen Litwin, William D T Kent, Daniel D Holloway, Jill Roy, Robert J H Miller, Sharon Chih, Ryan A Davey, Debra L Isaac, Nakul Sharma, Kristin J Lyons, Jonathan G Howlett

Canadian Journal of Cardiology · 2024

DOI: 10.1016/j.cjca.2023.11.017 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Canadian Journal of Cardiology, 2024. Verfasst von Nowell M Fine und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Cardiac Sciences, Libin Cardiovascular Institute, Cumming School of Medicine, Calgary, Alberta, Canada. Electro…. Hauptthemen laut MEDLINE: Heart Failure, Heart-Assist Devices, Ventricular Dysfunction, Left, Ventricular Dysfunction, Right. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben. Gefördert von: Pfizer Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureHeart-Assist DevicesVentricular Dysfunction, LeftVentricular Dysfunction, RightHumansFeasibility StudiesRetrospective StudiesSildenafil CitrateTreatment OutcomeClinical Trials as Topic

Substanzen

Sildenafil Citrate

Autor:innen und Institutionen

  • Division of Cardiology, Department of Cardiac Sciences, Libin Cardiovascular Institute, Cumming School of Medicine, Calgary, Alberta, Canada. Electronic address: nmfine@ucalgary.ca.
  • Division of Cardiology, Department of Cardiac Sciences, Libin Cardiovascular Institute, Cumming School of Medicine, Calgary, Alberta, Canada.
  • Division of Cardiac Surgery, Department of Cardiac Sciences, Libin Cardiovascular Institute, Cumming School of Medicine, Calgary, Alberta, Canada.
  • Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
  • Division of Cardiology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

Förderung

  • Pfizer Canada

Zitieren

APA

Fine, N. M., Litwin, O., Kent, W. D. T., Holloway, D. D., Roy, J., Miller, R. J. H., Chih, S., Davey, R. A., Isaac, D. L., Sharma, N., Lyons, K. J., & Howlett, J. G. (2024). Feasibility of Sildenafil for the Prevention of Right Heart Failure After Continuous-Flow Left Ventricular Assist Device Implantation: The REVAD Trial. Canadian Journal of Cardiology. https://doi.org/10.1016/j.cjca.2023.11.017

Vancouver

Fine NM, Litwin O, Kent WDT, Holloway DD, Roy J, Miller RJH, et al. Feasibility of Sildenafil for the Prevention of Right Heart Failure After Continuous-Flow Left Ventricular Assist Device Implantation: The REVAD Trial. Canadian Journal of Cardiology. 2024. doi:10.1016/j.cjca.2023.11.017

BibTeX
@article{Fine2024,
  author = {Fine, Nowell M and Litwin, Owen and Kent, William D T and Holloway, Daniel D and Roy, Jill and Miller, Robert J H and Chih, Sharon and Davey, Ryan A and Isaac, Debra L and Sharma, Nakul and Lyons, Kristin J and Howlett, Jonathan G},
  title = {Feasibility of Sildenafil for the Prevention of Right Heart Failure After Continuous-Flow Left Ventricular Assist Device Implantation: The REVAD Trial},
  journal = {Canadian Journal of Cardiology},
  year = {2024},
  doi = {10.1016/j.cjca.2023.11.017}
}
Kostenlos starten →